Aerovate Therapeutics (AVTE) Competitors $2.37 -0.02 (-0.84%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 02/21/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVTE vs. KRRO, NMRA, YMAB, KOD, TVGN, NGNE, ACIU, HRTX, ELDN, and ITOSShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Tevogen Bio (TVGN), Neurogene (NGNE), AC Immune (ACIU), Heron Therapeutics (HRTX), Eledon Pharmaceuticals (ELDN), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Korro Bio Neumora Therapeutics Y-mAbs Therapeutics Kodiak Sciences Tevogen Bio Neurogene AC Immune Heron Therapeutics Eledon Pharmaceuticals iTeos Therapeutics Korro Bio (NASDAQ:KRRO) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations. Does the MarketBeat Community believe in KRRO or AVTE? Korro Bio received 5 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Korro Bio an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformKorro BioOutperform Votes24100.00% Underperform VotesNo VotesAerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% Which has more risk and volatility, KRRO or AVTE? Korro Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Which has stronger valuation and earnings, KRRO or AVTE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro BioN/AN/A-$81.17MN/AN/AAerovate TherapeuticsN/AN/A-$75.52M-$2.99-0.79 Do insiders and institutionals hold more shares of KRRO or AVTE? 13.2% of Korro Bio shares are held by institutional investors. 5.4% of Korro Bio shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor KRRO or AVTE? In the previous week, Korro Bio and Korro Bio both had 1 articles in the media. Aerovate Therapeutics' average media sentiment score of 1.95 beat Korro Bio's score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aerovate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer KRRO or AVTE? Korro Bio presently has a consensus target price of $144.00, suggesting a potential upside of 447.74%. Aerovate Therapeutics has a consensus target price of $2.25, suggesting a potential downside of 5.06%. Given Korro Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Korro Bio is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is KRRO or AVTE more profitable? Korro Bio's return on equity of -50.25% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -50.25% -38.48% Aerovate Therapeutics N/A -90.19%-77.47% SummaryKorro Bio beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.01M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.796.1326.4618.82Price / SalesN/A313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book0.606.747.634.64Net Income-$75.52M$138.11M$3.18B$245.69M7 Day Performance-3.27%-2.43%-1.91%-2.66%1 Month Performance-6.32%-1.91%-0.19%-2.15%1 Year Performance-87.41%-5.03%16.70%12.90% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics0.6147 of 5 stars$2.37-0.8%$2.25-5.1%-87.4%$69.01MN/A-0.7920Positive NewsKRROKorro Bio0.917 of 5 stars$30.02+3.2%$144.00+379.7%-51.4%$281.29MN/A0.0070News CoverageGap UpNMRANeumora Therapeutics4.079 of 5 stars$1.74+3.0%$16.50+848.3%-90.0%$281.11MN/A-0.93108News CoverageYMABY-mAbs Therapeutics2.5762 of 5 stars$6.24+1.1%$20.89+234.8%-65.3%$279.49M$84.82M-11.56150News CoverageKODKodiak Sciences4.2475 of 5 stars$5.26+3.1%$8.00+52.1%-14.6%$276.78MN/A-1.4490Positive NewsTVGNTevogen Bio3.3832 of 5 stars$1.58+1.3%$4.20+165.8%-82.1%$276.58MN/A0.003NGNENeurogene2.2421 of 5 stars$18.42-1.9%$60.83+230.3%-41.7%$273.63M$925,000.000.0090ACIUAC Immune2.2101 of 5 stars$2.74+2.2%$12.00+338.0%-21.0%$271.10M$16.48M-5.96140News CoveragePositive NewsGap UpHigh Trading VolumeHRTXHeron Therapeutics3.9187 of 5 stars$1.78+7.9%$5.67+218.4%-37.1%$270.74M$127.04M-9.89300ELDNEledon Pharmaceuticals2.1135 of 5 stars$4.53+0.9%$12.50+175.9%+130.6%$270.62MN/A-2.2510ITOSiTeos Therapeutics3.1188 of 5 stars$7.40+1.8%$22.25+200.7%-29.8%$270.32M$12.60M-2.3590Positive News Related Companies and Tools Related Companies Korro Bio Competitors Neumora Therapeutics Competitors Y-mAbs Therapeutics Competitors Kodiak Sciences Competitors Tevogen Bio Competitors Neurogene Competitors AC Immune Competitors Heron Therapeutics Competitors Eledon Pharmaceuticals Competitors iTeos Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
